GSOA
15.12.2021 17:35:10 CET | Business Wire | Press release
Chief Executives of the world’s leading satellite operators announced today in Paris on the occasion of World Satellite Business Week 2021 that ESOA, the EMEA Satellite Operators Association, is expanding to include satellite operators from all world regions and will change its name to GSOA, the Global Satellite Operators’ Association. They also announced that seven new members – Amazon, APT, ARSAT, Intersputnik, Lockheed Martin, Omnispace and Star One – had already agreed to join GSOA.
GSOA will remain the only CEO-driven satellite industry association. It will focus on a core mission of providing a unified voice and a platform for collaboration for satellite operators globally to ensure their continued success and for broadening the opportunities for policymakers and industry players to leverage satellite services to fulfil their objectives.
“The creation of GSOA reflects a strong belief in the satellite communications sector that a strong, global voice is needed to ensure that the sector is well positioned to helping create a more connected and sustainable world,” said Stephen Spengler, ESOA Chairman and CEO of Intelsat. “The fact that new members are already joining us is a demonstration of support for GSOA’s mission and the need to ensure that, together, we have a strong voice in shaping the communications ecosystem of the future.”
Leading Change
GSOA is structured to drive industry leadership in the face of three key trends: unparalleled innovation in the space sector, an insatiable demand for all types of connectivity, and a need to bring sustainability to space. In this regard, the GSOA Board has approved three broad industry goals.
GSOA is committed to:
On earth: extending connectivity globally where other networks don’t, connecting unconnected communities, schools, households, planes, ships, businesses, humanitarian agencies, peacekeepers and governments, aiming to increase the number of satellite data connections by 250% by 2030 and increase the data consumed by those connections 15 fold.
In space: preserving the space environment for future generations by designing, launching and operating satellites in a responsible way and minimising the creation of space debris.
For all: supporting the UN Sustainable Development Goals by providing access to secure, reliable and sustainable broadcast & broadband connectivity to people, schools, enterprises, organisations and devices wherever they may be, whether on the move, at work, or at play.
ESOA to GSOA
With the industry’s multi-orbit offering, the satellite sector will respond to the great majority of connectivity requirements presented by the data driven economy of tomorrow. From bridging crippling social, education, healthcare and other divides that exist due to the lack of communications infrastructure on all continents to enabling a host of 5G and IoT use cases for different vertical sectors.
Satellite operators will continue to build on the successes of ESOA which include providing the support the industry needed to push ahead with 5G standards and vital leadership on issues such as satellite spectrum and space sustainability. Through GSOA, the satellite sector will now be able to drive such global activities leveraging a global operator base.
GSOA will provide its members with the opportunity to shape the future of the satellite communications industry and the frameworks in which it operates by participating in key activities that impact the sector. Specifically, GSOA members will be able to engage in cross-sector initiatives, drive common positions, represent the industry on topics such as spectrum and 5G in events on all continents and contribute to ITU work concerning the development agenda, emergency communications and of course spectrum.
The association will continue to have a CEO-led Board, which has proved invaluable to the success of the ESOA to date, a strong Secretariat, and member-driven working groups that execute the broad agenda set by the Board.
“This is an important change that will help ensure the industry is positioned well into the future ”, said Aarti Holla-Maini, the secretary general of ESOA. “We also recognize that there are other industry associations who will want to understand the implications of this change and we look forward to working with them to ensure the satellite communications sector has the strongest possible, unified global voice .”
The Global Satellite Operators Association now counts among its members: Airbus CIS, Amazon, Amos Spacecom, APT, Arabsat, Arsat, Avanti, Azercosmos, Echostar-Hughes, HellasSat, Hispasat, Inmarsat, Intelsat, Intersputnik, Lockheed Martin, Nigcomsat, Nilesat, Omnispace, OneWeb, Rascomstar, SES, SSI-Monacosat, Star One, Telenor, Telesat, Telespazio, Thuraya, Turksat, Viasat and Yahsat as well as representatives of the broader space industry including Airbus Defence and Space, Arianespace, Astroscale, Mansat, ST Engineering and Thales Alenia Space.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005734/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
